Fuda Cancer Hospital
Fuda Cancer Hospital
Chiny, Kanton
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
China treats chordoma through aggressive surgery and advanced particle radiation therapy within specialized multidisciplinary centers. Surgeons prioritize wide en bloc resection for spinal cases or endoscopic transnasal surgery for skull-base tumors. Treatment plans often combine high-precision carbon ion or proton beams to eliminate remaining microscopic disease.
Bookimed Expert Insight: Xiamen Humanity Hospital stands out for its massive scale, serving nearly 1,000,000 patients annually. This high volume across 47 departments allows for rapid multidisciplinary collaboration. Professor Liu Shi Xin at this facility holds high-level certifications in radiation oncology. His expertise in VMAT and SBRT is vital for chordoma patients who cannot access carbon ion centers.
Patient Consensus: Patients note that successful outcomes depend on surgeons achieving full removal without nerve damage. They frequently emphasize that coordinated planning between surgical and radiation teams is more important than the operation alone.
Chordoma treatment in China involves surgical risks like nerve injury, hemorrhage, and anesthesia reactions. Post-operative hurdles include cerebrospinal fluid leaks, wound infections, and blood clots. Long-term impacts may include permanent nerve deficits, chronic neuropathic pain, and bowel or bladder dysfunction depending on tumor location.
Bookimed Expert Insight: China's large-scale hospitals like Xiamen Humanity Hospital manage around 1,000,000 patients every year. This massive clinical volume allows surgeons there to see rare chordoma cases more frequently than many Western centers. When choosing a facility, look for those with JCI accreditation and specialized neuro-oncology teams to ensure safety protocols match international standards despite the high patient turnover.
Patient Consensus: Patients note that regaining basic functions like walking or swallowing takes much longer than expected. Many emphasize that long-term physical therapy and bowel retraining are necessary parts of the recovery journey.
Proton Beam Therapy (PBT) uses light particles with low-energy transfer to minimize toxicity. Carbon Ion Radiotherapy (CIRT) employs heavy particles to destroy radioresistant chordoma cells. While both utilize the Bragg peak for precision, CIRT offers higher biological effectiveness and destroys oxygen-deprived tumor zones.
Bookimed Expert Insight: While machine type is important, clinical leadership in China is a key quality signal. Dr. Liu Shi Xin at Xiamen Humanity Hospital serves as Vice Chairman of the Particle Therapy Professional Committee. This institutional expertise is crucial for chordoma, as specialized centers can manage over 1,000,000 annual patient visits while maintaining JCI standards.
Patient Consensus: Patients note that while CIRT hits harder against resistant tumors, PBT is primarily valued for sparing healthy tissue near the spine. Success often depends on having a skilled surgical resection before starting any particle therapy.
Shanghai and Guangzhou serve as Chinas primary hubs for chordoma treatment within Tier-1 cities. These centers integrate medical particle accelerators with multidisciplinary teams specializing in skull base and sacral tumors. Shanghai specifically provides unique access to both proton and carbon ion radiotherapy for radioresistant bone malignancies.
Bookimed Expert Insight: While machine access is critical, specialized leadership often dictates outcomes. Dr. Liu Shi Xin at Xiamen Humanity Hospital is a leading figure in the Chinese Anti-Cancer Association particle therapy committee. This connection ensures patients receive treatment at a facility where the infrastructure is matched by national-level expertise in precise radiation protocols.
Patient Consensus: Patients emphasize finding a center that coordinates surgery and specialized radiation under one roof. They note that the first surgery is critical and prefer teams with high chordoma-specific volume.
China offers unique advantages for chordoma treatment due to its role as a global leader in carbon ion radiotherapy. This rare modality is essential for destroying radioresistant tumor cells near the spine. Patients benefit from exceptionally high surgical volumes and streamlined paths to specialized multidisciplinary care.
Bookimed Expert Insight: While many countries have specialized oncology centers, China stands out for institutional scale. Xiamen Humanity Hospital alone serves 1,000,000 patients annually. At Fuda Cancer Hospital, specialists have treated 30,000+ international patients from over 100 countries. This massive volume means multidisciplinary teams handle rare cases like chordoma daily. Professor Liu Shi Xin at Xiamen Humanity Hospital holds leadership roles in national particle therapy committees. This level of specialization often leads to more refined planning for tumors near critical structures.
Patient Consensus: Patients value the speed of access and lower costs compared to Western centers. They emphasize choosing specific surgeons with high-volume experience rather than just a hospital.
Outpatient treatment timelines for proton or carbon ion therapy in China typically span 1 to 6 weeks. Carbon ion therapy often concludes within 1 to 4 weeks due to higher biological impact. Standard proton therapy for chordoma usually requires 5 daily sessions per week for 4 to 8 weeks.
Bookimed Expert Insight: While carbon ion therapy offers shorter schedules, chordoma treatment often requires the full 6–8 week proton protocol for skull-base precision. Hospitals like Xiamen Humanity Hospital manage massive volumes of 1,000,000 annual patients. This scale ensures high-level expertise in complex radiation oncology. Professor Liu Shi Xin at Xiamen is a national leader in particle therapy committees. His leadership indicates that Chinese centers prioritize rigorous academic oversight for these advanced technologies.
Patient Consensus: Patients note the treatment feels more like a daily job than a medical procedure. The main challenge is the daily repetition and staying in nearby housing rather than the short beam time.